AnaptysBio, Inc. (ANAB)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS0327241065
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by AnaptysBio, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:22. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 12 Nov 2026 16:00 | 0.53 | 0.11 | -79.1% | Miss |
| 21 Sep 2026 16:00 | 0.14 | 4.93 | +3,384.4% | Beat |
| 03 Mar 2026 16:00 | 0.93 | 1.58 | +69.3% | Beat |
| 04 Nov 2025 16:00 | -1.25 | 0.52 | +141.6% | Beat |
| 06 Aug 2025 16:00 | -1.58 | -1.34 | +15.3% | Beat |
| 05 May 2025 16:00 | -1.46 | -1.28 | +12.5% | Beat |
| 27 Feb 2025 16:00 | -1.70 | -0.72 | +57.8% | Beat |
| 05 Nov 2024 16:00 | -1.61 | -1.14 | +29.3% | Beat |
| 05 Aug 2024 16:00 | -0.93 | -1.71 | -83.5% | Miss |
| 09 May 2024 16:00 | -1.60 | -1.64 | -2.7% | Miss |
| 11 Mar 2024 16:00 | -1.49 | -1.59 | -6.4% | Miss |
| 02 Nov 2023 16:00 | -1.89 | -1.41 | +25.4% | Beat |
| 07 Aug 2023 16:00 | -1.74 | -1.50 | +14.0% | Beat |
| 11 May 2023 16:00 | -1.02 | -1.58 | -54.3% | Miss |
| 01 Mar 2023 16:00 | -0.94 | -0.93 | +1.3% | Beat |
| 08 Nov 2022 16:00 | -0.63 | -1.18 | -88.4% | Miss |
| 08 Aug 2022 17:00 | -1.07 | -1.15 | -7.5% | Miss |
| 04 May 2022 16:00 | -1.01 | -1.31 | -29.8% | Miss |
| 07 Mar 2022 08:00 | 3.99 | -1.18 | -129.6% | Miss |
| 04 Nov 2021 16:00 | -0.98 | -0.24 | +75.5% | Beat |
| 09 Aug 2021 16:00 | -0.03 | -0.02 | +26.7% | Beat |
| 04 May 2021 16:00 | -0.83 | -0.66 | +20.1% | Beat |
| 25 Feb 2021 16:00 | 0.60 | 1.20 | +98.9% | Beat |
| 04 Nov 2020 16:00 | -0.69 | -0.87 | -26.5% | Miss |
| 10 Aug 2020 08:00 | -0.65 | -0.79 | -21.2% | Miss |
| 06 May 2020 16:00 | -0.80 | -0.30 | +62.5% | Beat |
| 02 Mar 2020 08:00 | -1.28 | -0.75 | +41.4% | Beat |
| 08 Nov 2019 08:00 | -1.14 | -1.15 | -0.5% | In line |
| 08 Aug 2019 16:00 | -0.95 | -0.89 | +6.7% | Beat |
| 07 May 2019 16:00 | -0.78 | -0.82 | -4.8% | Miss |
| 28 Feb 2019 05:00 | -0.86 | -0.64 | +25.9% | Beat |
| 08 Nov 2018 16:00 | -0.70 | -0.66 | +6.2% | Beat |
| 07 Aug 2018 06:00 | -0.67 | -0.57 | +14.4% | Beat |
| 08 May 2018 16:00 | -0.46 | -0.63 | -36.2% | Miss |
| 05 Mar 2018 16:00 | -0.42 | -0.30 | +28.4% | Beat |
| 07 Nov 2017 06:00 | -0.47 | -0.45 | +4.6% | Beat |
| 10 Aug 2017 16:00 | -0.42 | -0.13 | +69.3% | Beat |
| 11 May 2017 16:00 | -0.18 | -0.75 | -311.0% | Miss |
| 08 Mar 2017 16:00 | -0.10 | -0.19 | -86.3% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 234.6M | +157.0% | -13.2M | -5.6% | -0.46 | +91.0% | 19.7M |
| 2024 | 91.3M | +432.0% | -145.2M | -159.1% | -5.12 | +15.8% | -135.3M |
| 2023 | 17.2M | +66.8% | -163.6M | -953.7% | -6.08 | -33.0% | -121.6M |
| 2022 | 10.3M | — | -128.7M | -1,251.3% | -4.57 | — | -74M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 12 Nov 2026 In progress | 47.03 | 49.15 | 46.19 | 47.77 | +2.84% | 1,062,300 | |
| 02 Nov 2026 – 06 Nov 2026 | 48.33 | 49.00 | 45.01 | 46.45 | -3.79% | 1,782,800 | |
| 26 Oct 2026 – 30 Oct 2026 | 48.97 | 51.22 | 47.88 | 48.28 | -0.92% | 1,784,500 | |
| 19 Oct 2026 – 23 Oct 2026 | 47.33 | 51.86 | 44.02 | 48.73 | +4.55% | 3,061,600 | |
| 12 Oct 2026 – 16 Oct 2026 | 46.16 | 48.83 | 45.00 | 46.61 | +1.44% | 2,112,100 | |
| 05 Oct 2026 – 09 Oct 2026 | 48.53 | 49.84 | 44.74 | 45.95 | -5.32% | 3,038,500 | |
| 28 Sep 2026 – 02 Oct 2026 | 51.00 | 52.02 | 48.13 | 48.53 | -4.84% | 3,473,700 | |
| 21 Sep 2026 – 25 Sep 2026 | 56.00 | 56.04 | 49.45 | 51.00 | -7.61% | 2,915,200 | |
| 14 Sep 2026 – 18 Sep 2026 | 54.58 | 55.79 | 53.22 | 55.20 | +2.47% | 2,491,100 | |
| 08 Sep 2026 – 11 Sep 2026 | 55.48 | 58.17 | 53.75 | 53.87 | -5.16% | 1,968,100 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside? (opens in a new tab) Insider Monkey · 31 Oct 2026 21:17
- Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval? (opens in a new tab) Simply Wall St. · 30 Oct 2026 07:10
- AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (opens in a new tab) Zacks · 27 Oct 2026 13:00
- Why This IPO Stock, An AnaptysBio Spinoff, Just Surged (opens in a new tab) Investor's Business Daily · 12 Oct 2026 21:10
- AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story (opens in a new tab) Simply Wall St. · 09 Oct 2026 05:29
- AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise (opens in a new tab) Simply Wall St. · 09 Oct 2026 00:17
- AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance (opens in a new tab) Simply Wall St. · 26 Sep 2026 15:11
- AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns? (opens in a new tab) Insider Monkey · 26 Sep 2026 04:38
- AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (opens in a new tab) Zacks · 21 Sep 2026 22:35
- Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) (opens in a new tab) Insider Monkey · 14 Sep 2026 19:34
- GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control (opens in a new tab) Insider Monkey · 17 Aug 2026 16:03
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 48.77 USD
- Market cap
- 1.4B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 12.5 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 6.2 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 9.2 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Heavy debt: net debt is 12.1× EBITDA
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 10.4× | Good | 14.16× |
| Price / book | 68.73× | Weak | 3.5× |
| Price / sales | 23.78× | Weak | 3.33× |
| EV / EBITDA | 169.67× | Weak | 11.19× |
| Free cash flow yield | 1.4% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 108.9% | Good | 54.9% |
| Operating margin | 15% | Fair | 5.8% |
| Net margin | 417.6% | Good | 1.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 183.6% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 12.6× | Weak | 0.4× |
| Net debt / EBITDA | 12.13× | Weak | 1.46× |
| Interest cover | 2.84× | Weak | 2.17× |
| Current ratio | 8.4× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow ANAB and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.